Please assess the completion status of the following clinical trial:

Trial Title: Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic melanoma: Either unresectable Stage III or any Stage IV~* ECOG of 0 or 1~* HLA-A\*0201 haplotype~* Baseline tumor biopsy MART1/Melan-A expression present (in \>10% of tumor cells)~* Patient provides consent for all required biopsies~* Adequate intravenous access for leukapheresis~* Absolute lymphocyte count \>500/ul at least once within 30 days of leukapheresis~* Life expectancy greater than 4 months in the opinion of the study clinician~* Negative pregnancy test~Exclusion Criteria:~* Administration of systemic corticosteroids within 28 days of planned leukapheresis~* Administration of cytotoxic chemotherapy or anti-tumor immunotherapy within 28 days of planned leukapheresis~* Administration of radiotherapy within 28 days of planned leukapheresis with the exception of subjects accrued to Cohort 3~* Active autoimmunity requiring systemic immunosuppressive therapy~* HIV infection~* Previous enrollment on this protocol and infusion of MART1/Melan-A CTL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Different dose of CTL
- Cohort 2 (Type: EXPERIMENTAL): Different dose of CTL
- Cohort 3 (Type: EXPERIMENTAL): Combination of CTL with GMCSF +/- radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).